Global Cannabis Lifestyle Brand Marley Natural Makes European Debut at Iconic French Retailer colette
5.7.2017 09:00 | Business Wire
Marley Natural™, the official Bob Marley cannabis lifestyle brand, made its European debut at the iconic French retailer colette during couture fashion week in Paris. Marley Natural and colette celebrated the occasion at a pop-up developed in collaboration with System Magazine and the fashion design duo Creatures of the Wind.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170704005378/en/
Naturally-derived cannabis sativa body care infused with Jamaican botanicals by Marley Natural (Photo: Business Wire)
“From Trenchtown to Paris, my grandfather’s music and message are universal,” said Zuri Marley, Bob Marley’s granddaughter, who hosted and curated music for the launch event. “By bringing Marley Natural to Europe, we are celebrating, sharing, and spreading Bob’s belief in the positive potential of the herb to heal, inspire and create.”
Marley Natural body care products and smoking accessories are available from colette online and in-store at 213 rue Saint-Honoré. In addition to Marley Natural products, the shop will also feature a limited-edition cannabis-inspired collection by Creatures of the Wind and System Magazine’s Issue No. 9, which includes a 140-page portfolio shot by photographer Juergen Teller at a Canadian medical cannabis facility.
Drawing on System’s latest issue theme of cannabis, the Creatures of the Wind capsule collection features hand-drawn botanical embroidery by designers Chris Peters and Shane Gabier. The capsule, which is comprised of four styles (parkas, fur coats and one-of-a-kind vintage sweater and t-shirts), is being sold at colette starting on Tuesday, July 4.
About Marley Natural
Marley Natural™ is a premium product line crafted with awareness, authenticity, and a genuine respect for nature’s nourishing benefits. Our flower, accessories, and body care products are all responsibly sourced and integrity driven. Each of our offerings is a direct reflection of the Marley ethos that integrates nature’s goodness with a belief in the positive potential of herb. As agents of change, we promote positivity, connectivity, and personal transformation. And as believers in progress, we offer an exceptional lifestyle line that is inspired by Jamaica’s vibrant energy. We are proud to be the official Bob Marley cannabis brand.
About Marley Natural Products
Naturally-Derived Cannabis Sativa Body Care Infused with Jamaican Botanicals
The Marley Natural body care line offers naturally-derived formulas that blend the moisturizing power of hemp seed oil with Jamaican botanicals, including ginger, lemongrass, turmeric, and cerasse. All formulas contain cold-pressed hemp seed oil rich in essential fatty acids, Omega-3s and Omega-6s. All formulas are paraben, sulfate and cruelty free. Body care products are available for sale via www.MarleyNaturalShop.com. The hemp seed body care products include an essential oil blend, body lotion, body wash, body salve, hand cream, bar soap and a lip balm.
Sustainably Sourced American Black Walnut Smoking Accessories
Balancing intuitive design with Jamaican-inspired accents, Marley Natural’s smoking accessories cater to discerning herb connoisseurs who celebrate the ritual of smoking. The collection features products made from sustainably sourced American Black Walnut wood and heat-resistant, hand-blown glass, all boxed in 100% recyclable packaging. Each product is designed to ensure durability, convenient maintenance, and a comfortable hand-feel. The accessories are designed to be used only with legal smoking herbs and are not intended to be used with tobacco products. The collection is available for sale at specialty retailers in the United States and Europe, as well as online at www.MarleyNaturalShop.com. The collection includes a taster, a spoon pipe, a steamroller, a bubbler, and a grinder, as well as prep trays and storage devices.
About System Magazine
System explores with style and substance the dialogues at the heart of the global fashion industry. Its biannual magazine offers exclusive long-format conversations with fashion’s most relevant, most powerful and most opinionated individuals, accompanied by portfolios created by the industry’s most in-demand image-makers. Exploring and commenting on fashion’s constantly shifting landscape, System is a platform for deep thoughts and real opinions – shared within the industry and, in turn, influencing the broader world.
Berrin Noorata, +1-917-208-1639
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 16:00 | Tiedote
Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of
Acxiom Launches Connected Spaces27.7.2017 15:30 | Tiedote
Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative
Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 15:08 | Tiedote
On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to
European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 14:05 | Tiedote
Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney
Subscription Period for Superior Industries’ Tender of UNIWHEELS AG’s Shares to Close Monday, July 31, 201727.7.2017 09:00 | Tiedote
Superior Industries International, Inc. (NYSE:SUP), one of the world’s largest manufacturers of aluminum wheels, reiterated today that the subscription period for the tender offer to acquire all remaining outstanding shares of UNIWHEELS AG (“UNIWHEELS”) will close Monday, July 31, 2017. On June 30, 2017, Superior announced it had commenced a tender offer to acquire the remaining 954,920 shares held by the public shareholders, which represents approximately 7.7% of the total outstanding shares of UNIWHEELS, for cash consideration of 247.87zl per share. Superior acquired the other approximately 92.3% of the outstanding shares through a tender offer that was settled on May 30, 2017, where the public shareholders also received cash consideration of 247.87zl per share. Following the settlement of the tender offer, Superior will finalize the proceedings to delist UNIWHEELS’ common stock from
Ipsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 201727.7.2017 08:00 | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2017. H1 2017 Highlights Strong operating performance of 18.8%1 Group sales growth and Core Operating Income margin improvement by 1.2 points to 26.2% of sales Specialty Care sales growth of 23.1%1 reflects continued Somatuline® momentum and includes contribution of key new products Cabometyx® and Onivyde® Consumer Healthcare sales growth of 1.3%1 including contribution of newly acquired products Upgraded full year 2017 guidance of Specialty Care sales growth greater than 24.0%1, slight growth1 of Consumer Healthcare sales, and Core Operating Income margin greater than 25.0% o
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme